TABLE 1.
Characteristics of breast cancer cases and matched controls
| Cases, n = 68 816 | Controls, n = 688 160 | |
|---|---|---|
| Age, median (IQR, years) | 62 (53‐70) | 62 (53‐70) |
| Use of low‐dose aspirin, n (%) | ||
| Never | 60 268 (88%) | 603 363 (88%) |
| Ever | 8548 (12%) | 84 797 (12%) |
| Long‐term | 5186 (7.5%) | 50 867 (7.4%) |
| Cumulative DDDs, median (IQR) | 1300 (500‐2500) | 1300 (500‐2470) |
| Use of clopidogrel, n (%) | ||
| Never | 67 737 (98%) | 676 397 (98%) |
| Ever | 1079 (1.6%) | 11 763 (1.7%) |
| Long‐term | 287 (0.4%) | 2981 (0.4%) |
| Cumulative DDDs, median (IQR) | 500 (340‐1074) | 448 (330‐1000) |
| Use of dipyridamole, n (%) | ||
| Never | 67 792 (99%) | 677 946 (99%) |
| Ever | 1024 (1.5%) | 10 214 (1.5%) |
| Long‐term | 527 (0.8%) | 5205 (0.8%) |
| Cumulative DDDs, median (IQR) | 1050 (360‐2130) | 1034 (360‐2100) |
| Ever use of other drugs, n (%) | ||
| Antidiabetics | 3432 (5.0%) | 33 756 (4.9%) |
| Statins | 10 504 (15%) | 106 227 (15%) |
| Spironolactone | 1127 (1.6%) | 10 182 (1.5%) |
| Loop diuretics | 4701 (6.8%) | 43 627 (6.3%) |
| Beta‐blockers | 2480 (3.6%) | 22 602 (3.3%) |
| Vascular calcium‐channel blockers | 8238 (12%) | 79 809 (12%) |
| Selective serotonin reuptake inhibitors | 10 532 (15%) | 100 842 (15%) |
| Raloxifene | 126 (0.2%) | 1986 (0.3%) |
| Recent use of oral contraceptives | 3053 (4.4%) | 24 678 (3.6%) |
| Former use of oral contraceptives | 13 729 (20%) | 130 851 (19%) |
| Recent use of hormone replacement therapy | 8434 (12%) | 48 379 (7.0%) |
| Former use of hormone replacement therapy | 18 162 (26%) | 146 237 (21%) |
| Comorbidities, n (%) | ||
| Alcohol related diseases | 2251 (3.3%) | 20 032 (2.9%) |
| Chronic obstructive pulmonary disease | 3354 (4.9%) | 31 051 (4.5%) |
| Hypertension | 30 618 (44%) | 296 223 (43%) |
| Hypercholesterolemia | 12 278 (18%) | 125 082 (18%) |
| Diabetes | 4127 (6.0%) | 40 489 (5.9%) |
| Acute myocardial infarction | 879 (1.3%) | 9558 (1.4%) |
| Other ischemic heart disease | 68 (0.1%) | 789 (0.1%) |
| Angina pectoris | 2536 (3.7%) | 25 757 (3.7%) |
| Heart failure | 931 (1.4%) | 8507 (1.2%) |
| Stroke | 1689 (2.5%) | 16 982 (2.5%) |
| Other cerebrovascular diseases | 992 (1.4%) | 10 092 (1.5%) |
| Atrial fibrillation or atrial flutter | 1948 (2.8%) | 16 319 (2.4%) |
| Pulmonary embolism and infarction | 342 (0.5%) | 3010 (0.4%) |
| Phlebitis and thrombophlebitis | 785 (1.1%) | 7124 (1.0%) |
| Portal vein thrombosis | 10 (0.0%) | 89 (0.0%) |
| Other venous embolism and thrombosis | 130 (0.2%) | 1020 (0.1%) |
| Charlson Comorbidity Index, n (%) | ||
| None (Score = 0) | 54 398 (79%) | 547 371 (80%) |
| Low (Score = 1) | 8760 (13%) | 88 909 (13%) |
| Medium (Score = 2) | 3326 (4.8%) | 30 579 (4.4%) |
| High (Score ≥ 3) | 2332 (3.4%) | 21 301 (3.1%) |
| Highest achieved education, n (%) | ||
| Basic (7‐10 years) | 198 (0.3%) | 3236 (0.5%) |
| Medium (11‐12 years) | 48 315 (70%) | 495 434 (72%) |
| Higher (≥13 years) | 18 845 (27%) | 174 428 (25%) |
| Unknown | 1458 (2.1%) | 15 062 (2.2%) |
Abbreviation: IQR, InterQuartile Range.